These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 19751915)

  • 1. Treatment effects of Memantine on language in moderate to severe Alzheimer's disease patients.
    Ferris S; Ihl R; Robert P; Winblad B; Gatz G; Tennigkeit F; Gauthier S
    Alzheimers Dement; 2009 Sep; 5(5):369-74. PubMed ID: 19751915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies.
    Mecocci P; Bladström A; Stender K
    Int J Geriatr Psychiatry; 2009 May; 24(5):532-8. PubMed ID: 19274640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe Impairment Battery Language scale: a language-assessment tool for Alzheimer's disease patients.
    Ferris S; Ihl R; Robert P; Winblad B; Gatz G; Tennigkeit F; Gauthier S
    Alzheimers Dement; 2009 Sep; 5(5):375-9. PubMed ID: 19751916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease.
    Wilkinson D; Andersen HF
    Dement Geriatr Cogn Disord; 2007; 24(2):138-45. PubMed ID: 17622761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled randomized trial.
    Pomara N; Ott BR; Peskind E; Resnick EM
    Alzheimer Dis Assoc Disord; 2007; 21(1):60-4. PubMed ID: 17334274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials.
    Winblad B; Jones RW; Wirth Y; Stöffler A; Möbius HJ
    Dement Geriatr Cogn Disord; 2007; 24(1):20-7. PubMed ID: 17496417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of memantine in delaying clinical worsening in Alzheimer's disease (AD): responder analyses of nine clinical trials with patients with moderate to severe AD.
    Hellweg R; Wirth Y; Janetzky W; Hartmann S
    Int J Geriatr Psychiatry; 2012 Jun; 27(6):651-6. PubMed ID: 22513699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial.
    Feldman H; Gauthier S; Hecker J; Vellas B; Xu Y; Ieni JR; Schwam EM;
    Int J Geriatr Psychiatry; 2005 Jun; 20(6):559-69. PubMed ID: 15920715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis.
    Gauthier S; Loft H; Cummings J
    Int J Geriatr Psychiatry; 2008 May; 23(5):537-45. PubMed ID: 18058838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment.
    Feldman HH; Schmitt FA; Olin JT;
    Alzheimer Dis Assoc Disord; 2006; 20(4):263-8. PubMed ID: 17132971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Donepezil treatment of severe Alzheimer's disease in nursing home settings. A responder analysis.
    Jelic V; Haglund A; Kowalski J; Langworth S; Winblad B
    Dement Geriatr Cogn Disord; 2008; 26(5):458-66. PubMed ID: 18984956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Donepezil preserves cognition and global function in patients with severe Alzheimer disease.
    Black SE; Doody R; Li H; McRae T; Jambor KM; Xu Y; Sun Y; Perdomo CA; Richardson S
    Neurology; 2007 Jul; 69(5):459-69. PubMed ID: 17664405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of donepezil on cognition in severe Alzheimer's disease: a pooled data analysis.
    Cummings J; Jones R; Wilkinson D; Lopez O; Gauthier S; Waldemar G; Zhang R; Xu Y; Sun Y; Richardson S; Mackell J
    J Alzheimers Dis; 2010; 21(3):843-51. PubMed ID: 20634594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Donepezil treatment of patients with severe Alzheimer's disease in a Japanese population: results from a 24-week, double-blind, placebo-controlled, randomized trial.
    Homma A; Imai Y; Tago H; Asada T; Shigeta M; Iwamoto T; Takita M; Arimoto I; Koma H; Ohbayashi T
    Dement Geriatr Cogn Disord; 2008; 25(5):399-407. PubMed ID: 18391486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies.
    Gauthier S; Wirth Y; Möbius HJ
    Int J Geriatr Psychiatry; 2005 May; 20(5):459-64. PubMed ID: 15852444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Domain-specific improvement of cognition on memantine in patients with Alzheimer's disease treated with rivastigmine.
    Riepe MW; Adler G; Ibach B; Weinkauf B; Tracik F; Gunay I
    Dement Geriatr Cogn Disord; 2007; 23(5):301-6. PubMed ID: 17356273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained effects of once-daily memantine treatment on cognition and functional communication skills in patients with moderate to severe Alzheimer's disease: results of a 16-week open-label trial.
    Schulz JB; Rainer M; Klünemann HH; Kurz A; Wolf S; Sternberg K; Tennigkeit F
    J Alzheimers Dis; 2011; 25(3):463-75. PubMed ID: 21471647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cognition and function in Alzheimer's disease: identifying the transitions from moderate to severe disease.
    Schwam E; Xu Y
    Dement Geriatr Cogn Disord; 2010; 29(4):309-16. PubMed ID: 20395684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Memantine enhances autonomy in moderate to severe Alzheimer's disease.
    Rive B; Vercelletto M; Damier FD; Cochran J; François C
    Int J Geriatr Psychiatry; 2004 May; 19(5):458-64. PubMed ID: 15156547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis.
    Schmitt FA; van Dyck CH; Wichems CH; Olin JT;
    Alzheimer Dis Assoc Disord; 2006; 20(4):255-62. PubMed ID: 17132970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.